What an interesting deal. J&J’s Ethicon, not known for its soft negotiating stance, has agreed a deal in which it pays Angiotech for IP relating to the company’s Quill suture technology, yet is allowing the pharma company to keep on selling it.
Sutures
Core Essence Receives FDA Approval For SECURUS™, An Innovative Knotless Suture Anchor System
Core Essence Orthopaedics, Inc. announced that it has received 510(k) regulatory approval from the Food and Drug Administration for SECURUS™, a novel knotless suture anchor system used in minimally invasive, arthroscopic surgery.